Harrow (HROW) Non Operating Interest Expenses (2010 - 2026)
Harrow (HROW) posted Non Operating Interest Expenses of $6.3 million for Q2 2026, up 13.93% on a QoQ basis from $5.5 million in Q1 2026, and down 2.26% year-over-year from $6.4 million in Q2 2025.
Analysis
Harrow (HROW) Non Operating Interest Expenses (2010 - 2026) Analysis & Trends
Harrow has reported Non Operating Interest Expenses for 14 years, with the latest figure at $6.3 million in Q2 2026.
- On a quarterly basis, Non Operating Interest Expenses fell 2.26% year-over-year to $6.3 million in Q2 2026; TTM through Jun 2026 was $23.0 million, a 7.53% decrease from a year earlier, with the FY2025 full-year figure at $24.2 million, up 6.12% from the prior year.
- Non Operating Interest Expenses was $6.3 million for Q2 2026 at Harrow, up from $5.5 million in the prior quarter.
- The five-year high for Non Operating Interest Expenses was $6.5 million in Q1 2025, with the low at $1.8 million in Q1 2022.
- Average Non Operating Interest Expenses over 5 years is $4.8 million, with a median of $5.5 million recorded in 2024.
- The sharpest annual moves came in 2022 and 2025: Non Operating Interest Expenses surged 249.32% in 2022, then fell 18.65% in 2025.
- Over 5 years, Non Operating Interest Expenses stood at $1.9 million in 2022, then soared by 175.78% to $5.1 million in 2023, then increased by 24.41% to $6.4 million in 2024, then decreased by 18.65% to $5.2 million in 2025, then gained by 20.77% to $6.3 million in 2026.
- The last three Non Operating Interest Expenses figures came in at $6.3 million (Q2 2026), $5.5 million (Q1 2026), and $5.2 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 642.70 Bn | 621.95 Bn | 17.26 Bn | 281.00 Mn |
| 2 | AbbVie | 440.80 Bn | 434.23 Bn | 12.70 Bn | - |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 266.37 Bn | 258.68 Bn | 11.24 Bn | -462.00 Mn |
| 5 | Pfizer | 158.89 Bn | 147.19 Bn | 10.94 Bn | - |
| 6 | Sanofi | 52.43 Bn | 45.05 Bn | 10.79 Bn | -333.60 Mn |
| 7 | Revolution Medicines | 44.38 Bn | 44.38 Bn | - | 23.78 Mn |
| 8 | Incyte | 25.28 Bn | 20.74 Bn | 1.57 Bn | 582,000.00 |
| 9 | United Therapeutics | 21.46 Bn | 18.80 Bn | 683.80 Mn | 2.90 Mn |
| 10 | Harrow | 1.41 Bn | 1.32 Bn | 50.36 Mn | 6.26 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 6.26 Mn |
| Mar 31, 2026 | 5.50 Mn |
| Dec 31, 2025 | 5.19 Mn |
| Sep 30, 2025 | 6.04 Mn |
| Jun 30, 2025 | 6.41 Mn |
| Mar 31, 2025 | 6.55 Mn |
| Dec 31, 2024 | 6.38 Mn |
| Sep 30, 2024 | 5.53 Mn |
| Jun 30, 2024 | 5.47 Mn |
| Mar 31, 2024 | 5.42 Mn |
| Dec 31, 2023 | 5.12 Mn |
| Sep 30, 2023 | 5.75 Mn |
| Jun 30, 2023 | 5.70 Mn |
| Mar 31, 2023 | 4.75 Mn |
| Dec 31, 2022 | 1.86 Mn |
| Sep 30, 2022 | 1.80 Mn |
| Jun 30, 2022 | 1.79 Mn |
| Mar 31, 2022 | 1.79 Mn |
| Dec 31, 2021 | 1.92 Mn |
| Sep 30, 2021 | 1.69 Mn |